Table 2.
Characteristics of Included Studies
| Primary reference, Study, Country (secondary references) | Objectives | Design | Sample size | Patient population | Follow-up |
|---|---|---|---|---|---|
| Treatment-related observational studies | |||||
| Driessen 2008[68], Radboud University Registry, The Netherlands (Driessen 2009[69]) | Efficacy and tolerability of etenercept and efalizumab | Registry | 118 | Psoriasis | 24 weeks |
| Fortune 2003[6], PUVA Study, UK and Ireland | Role of psychological distress on PUVA treatment outcomes | Cohort | 112 | Plaque psoriasis (chronic) | 2 years |
| Lecha 2005[70], Spanish tacalcitol ointment study | Efficacy and tolerability of tacalcitol | Cohort | 556 | Psoriasis (moderate) | 2 months |
| Naldi 2008[71], Psocare, Italy | Effect of BMI on clinical response to systemic treatment | Cohort | 2368 | Plaque psoriasis | 3 years |
| Paul 2003[72] Cyclosporine study, Europe and Canada | Incidence of malignancies in cyclosporine treated patients | Cohort | 1252 | psoriasis - severe | 5 years |
| Wahl 2005[73], Climate therapy study, Norway | Effectiveness of climate therapy | Cohort | 286 | Psoriasis | 8 months |
| Heiberg 2008[74], Norwegian register of disease modifying anti-rheumatic drugs, (Heiberg 2007[75]) | Comparative effectiveness of TNF inhibitors vs. methotrexate monotherapy | Registry | 526 | Psoriatic arthritis | 1 year |
| Kristensen 2008[76], South Swedish Arthritis Treatment Group register, (Gulfe 2009[77], Geborek 2002[78], Kristensen 2006[79]) | Efficacy, utility and tolerability of TNF-inhibitors (etanercept, infliximab, adalimumab) | Registry | 261 | Psoriatic arthritis | 7 years |
| Sparado 1997[80], Cyclosporin Study, Italy | Probability of continuing to take cyclosporine vs. other DMARDS | Cohort | 172 | Psoriatic arthritis | 10 years |
| Saad 2009[81], British Society for Rheumatology Biologics Register, (Harrison 2009[82], Silman 2003[83]) | Effectiveness and tolerability of TNF-inhibitors (etanercept, infliximab, adalimumab) | Registry | 566 | RA, psoriasis, psoriatic arthritis | 1 year |
| Non-treatment related observational studies | |||||
| Carrascosa 2006[84], EPIDERMA cost of illness, Spain | Direct and indirect cost; relationship between cost and severity | Cohort | 797 | Psoriasis | 1 year |
| Colombo 2008[11], Cost of illness, Italy | Direct and indirect cost; HRQOL; relationship between cost, HRQOL and severity | Cohort | 150 | Moderate to severe plaque psoriasis | 3 months |
| Schmid-ott 2005[85], Bad Bentheim Rehabilitation Hospital, Germany | Relationship between the degree of stigmatisation and gender, skin symptoms, PASI and SPASI | Cohort | 166 | Psoriasis | 1 year |
| Ali 2007[86], Husted 2007[2], Gladman 2009[16], Rohekar 2008[87], Toronto PsA clinic, Canada, (Chandran 2007[88], Gladman 1995[89], Gladman 1998[90], Gladman 1999 [91], Gladman 2001[92], Husted 2005[93], Wong 1997[94]) | (1) Mortality associated with PsA; (2) relationship between physical functioning, disease activity and joint damage; (3) CVD associated with PsA; (4) malignancies associated with PsA | Cohort | 382 to 680 | Psoriatic arthritis | 26 years |
| Kane 2003[95], St. Vincent's University study, Ireland, (Kane 2003a[96]) | Clinical presentation, outcome and prognosis of early PsA | Cohort | 129 | Early psoriatic arthritis | 2 years |
| Lindqvist 2008[97], SwePsA registry, Sweden, (Svensson 2002[98]) | Factors associated with disease progression; outcome of treated and non-treated groups, comparison of outcomes with RA patients | Registry | 135 | Early psoriatic arthritis | 2 years |
PUVA, Psoralen Ultra-Violet A. TNF, Tumor Necrosis Factor. DMARD, disease-modifying anti-rheumatic drug. RA, rheumatoid arthritis. HRQOL, health-related quality of life.